NOX — Noxopharm Cashflow Statement
0.000.00%
- AU$27.18m
- AU$28.10m
- AU$2.83m
Annual cashflow statement for Noxopharm, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 4.76 | 5.95 | 5.12 | 6.06 | 2.35 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -8.85 | -13.7 | -10.9 | -0.684 | -5.82 |
| Capital Expenditures | 0 | — | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.225 | 0 | 0.124 | 0 | 2.48 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.225 | 0 | 0.124 | 0 | 2.48 |
| Financing Cash Flow Items | -1.53 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 28.3 | 0.976 | -0.178 | 0 | 2.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 19.7 | -12.8 | -11 | -0.689 | -0.766 |